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The Mixed Lineage Leukemia (MLL) protein is an
important epigenetic regulator required for the main-
tenance of gene activation during development.MLL
chromosomal translocations produce novel fusion
proteins that cause aggressive leukemias in humans.
Individual MLL fusion proteins have distinct leukemic
phenotypes even when expressed in the same cell
type, but how this distinction is delineated on a
molecular level is poorly understood. Here, we high-
light a unique molecular mechanism whereby the
RUNX1 gene is directly activated by MLL-AF4 and
the RUNX1 protein interacts with the product of
the reciprocal AF4-MLL translocation. These results
support a mechanism of transformation whereby
two oncogenic fusion proteins cooperate by acti-
vating a target gene and then modulating the func-
tion of its downstream product.INTRODUCTION
Aberrant epigenetic changes are a driving force in many cancers
and are excellent candidates for the development of targeted
therapies (Dawson and Kouzarides, 2012). The design of such
therapies depends on a clear understanding of the molecular
details of disease progression. The Mixed Lineage Leukemia
(MLL) protein is an example of an important epigenetic protein
that is mutated in a subset of aggressive leukemias (Marschalek,
2010), and thus provides a useful model for studying the link
between epigenetic changes and cancer progression.
MLL is important for theepigeneticmaintenanceofgeneactiva-
tion and is required for normal hematopoietic development (Jude
et al., 2007;McMahon et al., 2007).MLL leukemogenicmutations116 Cell Reports 3, 116–127, January 31, 2013 ª2013 The Authorsinclude chromosomal translocations (commonly calledMLL rear-
rangements [MLLr]) that fuse the N terminus of theMLL gene in-
frame with any one of over 60 different partner genes, producing
novel fusion proteins (MLL-FPs). Almost 90% of all MLL-FPs are
fusionswithAF4,AF9,ENL, ELL, AF10,orAF6 (Meyer et al., 2009).
t(4;11)(q21;q23) chromosome translocations (referred to from
this point as t(4;11) translocations) fuse MLL in-frame with the
AF4 gene and produce both MLL-AF4 and AF4-MLL fusion
proteins (Bursen et al., 2004; Bursen et al., 2010). t(4;11) translo-
cations are a major cause of infant acute lymphoblastic leukemia
(ALL) and produce an aggressive disease with a poor prognosis.
Enforced expression ofMLL-AF4 alone is incapable of transform-
ing human CD34+ cord blood (Montes et al., 2011), and mouse
models expressing MLL-AF4 alone are not fully representative
of the human disease, instead producing B-cell lymphomas
(Chen et al., 2006; Metzler et al., 2006) acute myeloid leukemia
(AML), or precursor B-ALLs (pre-B-ALLs) (Krivtsov et al., 2008).
Conversely, expression of both MLL-AF4 and AF4-MLL together
result in either common lymphoid progenitor leukemia or mixed
lineage leukemia (MLL), a close recapitulation of the human
disease (Bursen et al., 2010). Unlike many acute leukemias,
t(4;11) leukemias are associated with very few cooperatingmuta-
tions (Bardini et al., 2010, 2011). This suggests that the t(4;11)
translocation by itself may be sufficient for leukemic transforma-
tion, perhaps because both MLL-AF4 and AF4-MLL fusion
proteinsarecapableof altering theepigenetic informationcontent
of the cell (Benedikt et al., 2011; Krivtsov et al., 2008). Interest-
ingly, knocking down the MLL-AF4 fusion protein alone is suffi-
cient to disrupt t(4;11) leukemic growth in vivo (Thomas et al.,
2005), indicating that targeting pathways controlled by the MLL-
AF4 protein could be effective in treating t(4;11) leukemias.
Wild-type MLL is proteolytically cleaved in vivo by Taspase 1
into N-terminal (MLL-N) and C-terminal (MLL-C) proteins, which
then dimerize in the presence of a large protein complex
(Dou et al., 2005; Hsieh et al., 2003; Nakamura et al., 2002; Yo-
koyama et al., 2002). MLL normally maintains activation of target
genes through multiple epigenetic mechanisms including the tri-
methylation of histone 3 on lysine 4 (H3K4Me3) via the activity of
its C-terminal SET domain, and through the recruitment of tran-
scriptional coactivators such as RBBP5, WDR5, ASH2L, and
the H4 acetyltransferase MOF (Dou et al., 2005; Milne et al.,
2002; Nakamura et al., 2002). MLL-FPs lack the C-terminal
SET domain, and five of the most commonMLL-FPs are constit-
uents of a large interactome that includes the transcriptional co-
activator complex pTEFb (a dimer of Cyclin T1 and CDK9;
Marshall and Price, 1995) and other members of a ‘‘super elon-
gation complex’’ (SEC) (Biswas et al., 2011; Lin et al., 2010;
Mueller et al., 2007; Yokoyama et al., 2010; Zeisig et al., 2005),
the H3K79methyltransferase DOT1L (Biswas et al., 2011; Okada
et al., 2005), the histone acetyl interacting bromodomain-con-
taining protein 4 (BRD4, amember of the BET family of bromodo-
main proteins) (Dawson et al., 2011; Zuber et al., 2011), aswell as
the polymerase associated factor 1 (PAF1) complex (Milne et al.,
2010; Muntean et al., 2010). The current model of MLL-FP func-
tion implicates BRD4 and PAF1 in recruitment of MLL-FPs and
the SEC to a subset of important target genes causing increased
transcription elongation (Biswas et al., 2011; Dawson et al., 2011;
Lin et al., 2010; Milne et al., 2010; Mueller et al., 2007; Muntean
et al., 2010; Yokoyama et al., 2010; Zuber et al., 2011). Interest-
ingly, AF4-MLL copurifieswith a pTEFb-containing complex, and
is thought to induce gene activation through a similar SEC
recruitment mechanism (Benedikt et al., 2011).
Although work with BRD4 inhibitors suggests that multiple
MLL-FPs use the same molecular pathway for leukemogenesis
(Dawson et al., 2011; Zuber et al., 2011), this cannot explain the
fact that MLL-AF4, MLL-AF9, and MLL-ENL produce different
leukemias even when expressed in the same cell type (Drynan
et al., 2005; Metzler et al., 2006). Furthermore, gene expression
analyses in t(4;11), MLL-ENL, and MLL-AF9 patient samples
display overlapping as well as distinct gene expression profiles
(Stam et al., 2010; Trentin et al., 2009), indicating that individual
MLL-FPs could activate unique gene expression pathways.
In this study, we set out to further analyze t(4;11) leukemias on
a molecular level. We initially used chromatin immunoprecipita-
tion sequencing (ChIP-seq) and MLL-AF4 small interfering
RNAs (siRNAs) in patient cell lines to identify key gene targets
regulated by MLL-AF4. One direct target of the MLL-AF4 protein
is the RUNX1 gene, a key hematopoietic transcription factor that
is specifically overexpressed in t(4;11) patient samples. Distinct
from other MLL-FPs, RUNX1 expression is important for the
growth of t(4;11) leukemia cell lines, in which it plays a role in
the activation of specific target genes. Furthermore, we show
that RUNX1 interacts with an AF4-MLL complex, providing a
new model of how MLL-AF4 and AF4-MLL cooperate on a
molecular level. Such a cooperative effect between these two
fusion proteins could explain some of the differences between
t(4;11) and other MLL-FP leukemias.
RESULTS
Common MLL-AF4 Target Genes Are Overexpressed
in Primary B-ALL Patient Samples
To identify potentially important direct target genes of MLL-AF4
in t(4;11) leukemias, we performed ChIP-seq in the RS4;11 cellCline and compared our results to a previously published data
set from SEM cells (Guenther et al., 2008). RS4;11 and SEM
cell lines are both t(4;11) pre-B-ALL patient-derived cell lines
(see Extended Experimental Procedures for details on cell lines)
that express the MLL-AF4 protein as well as wild-type MLL and
wild-type AF4.
No single antibody has been developed to uniquely recognize
endogenous MLL-AF4. Instead, using an approach originally
taken by Guenther et al. (2008), we performed ChIP-seq exper-
iments using antibodies against the N terminus of MLL (aMLL-N)
and the C terminus of AF4 (aAF4-C) (Figure 1A). To find actively
transcribed gene targets bound by MLL-AF4, we identified
promoters in RS4;11 cells enriched for both MLL-N and AF4-C
as well as H3K79Me2 (an active transcription elongation mark
that is highly enriched at important MLL-FP target genes;
Krivtsov et al., 2008; Milne et al., 2005) enrichment within the
gene body (Figures 1B–1D). We identified 603 gene targets
that met all three criteria (Figure 1D; Table S1). Two previously
identified direct targets of MLL-FPs, the HOXA cluster (Bernt
et al., 2011; Guenther et al., 2008; Milne et al., 2005) and
CDKN1B (Bernt et al., 2011; Xia et al., 2005), are shown as exam-
ples (Figure 1B and C). A similar approach with the SEM cell
ChIP-seq data set (Guenther et al., 2008) identified 2,490 puta-
tive MLL-AF4 target genes (Figure S1A; Table S1), which
produced a common overlap of 491 genes (Figure 1E; Table
S1). The 491 target set includes previously identified targets
such as JMJD1C, BCL2, FLT3, MYB, MYC, RUNX2, MEIS1,
CDKN1B, andHOXA cluster genes, as well as some other poten-
tially interesting gene targets such as EZH2, FOXP1, IZKF1,
IZKF2, and SOX4 (Table S1).
In MLLr B-ALL patient samples from three large clinical
studies, the average expression of the 491 MLL-AF4 target
genes was significantly higher than that of nontarget genes
(Figures 1F–1H and S1B–S1D). The 491 target gene set is also
significantly overexpressed in MLLr ALL compared to several
other B-ALL subtypes (E2A-PBX1, ETV6-RUNX1, and pre-B;
Figure S1E–S1G), although not others (e.g., BCR-ABL; Fig-
ure S1G). There is no significant difference between t(4;11) and
other MLLr patient samples (Figure 1I), suggesting that this 491
gene target set is generally overexpressed in patients with
MLLr ALLs. This correlation betweenChIP-seq and gene expres-
sion data in patient samples validates ChIP-seq in patient cell
lines as a powerful method to identify important target genes,
and also suggests that our 491 common MLL-AF4 targets
have an in vivo relevance to MLLr leukemia in human patients.
RUNX1 Is Overexpressed in Primary ALLs with t(4;11)
High expression of HOXA9, HOXA10, and MEIS1 is considered
to be a general hallmark of all MLL-FP leukemias, but a detailed
analysis of patient expression data show that many t(4;11)
leukemias do not express high levels of these genes (Stam
et al., 2010; Trentin et al., 2009), indicating that other addi-
tional targets are likely to have an important role in t(4;11)
leukemogenesis.
Among our list of 491 potential MLL-AF4 target genes, the
master hematopoietic transcription factor RUNX1 (AML1) is
highly enriched for MLL-N, AF4-C, H3K79Me2, and H3K4Me3 in
RS4;11 and also in SEM cells, at both of its two promoters, andell Reports 3, 116–127, January 31, 2013 ª2013 The Authors 117
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Figure 1. MLL-AF4 ChIP-Seq Target Genes
Are Upregulated in Primary B-ALLs
(A) Wild-type MLL is proteolytically cleaved
(dashed line) into N-terminal (MLL-N) and
C-terminal (MLL-C) proteins. The t(4;11) break-
point is marked by a black arrowhead labeled
‘‘bp.’’ The translocation fuses part of MLL-N in-
frame with AF4-C (red box), and also produces
a reciprocal AF4-MLL fusing AF4-N (violet box)
with the rest of MLL. Antibody positions on the
wild-type and fusion proteins are shown. A RUNX1
interaction domain at the C-terminal SET domain
(Huang et al., 2011) is indicated by blue shading.
(B and C) ChIP-seq in RS4;11 cells across the
HOXA cluster (B) and CDKN1B (C). The number of
reads for peak summits was normalized by the
total number of reads per track (set to 1 Gb for
each track). Four different primer sets used for
real-time PCRChIP analysis are shown (red boxes)
for the following amplicons: A9, A10, CDKN1B-A,
and -B.
(D) ChIP-seq in RS4;11 cells using antibodies to
MLL-N, AF4-C, and H3K79Me2 produced an
overlap at 603 target genes.
(E) Comparison between the 603 RS4;11 target
gene set from (D) and similar ChIP-seq data from
SEM cells (Guenther et al., 2008) produced a set of
491 common MLL-AF4 targets (see Table S1).
(F–I) The average expression of the 491 MLL-AF4
fusion target genes common in RS4;11 and SEM
cells have significantly higher (p < 1e-6, two-
tailed Wilcoxon test) expression levels than the
nontarget genes in MLLr B-ALL patients in
three different B-ALL clinical trials. (F) St. Jude
Children’s ResearchHospital, n = 20MLLr patients
(Ross et al., 2003). (G) COG P9906 clinical trial, n =
21 MLLr patients (Harvey et al., 2010). (H) ECOG
E2993 clinical trial, n = 25 MLLr patients (Geng
et al., 2012). (I) The same data as in (H), split into
t(4;11) versus other MLLr patient samples.
Boxplots (F–H) represent the median values
and error bars represent extreme maximum and
minimum whisker values for each plot. Bar plots (I)
are the mean and error bars represent SEM. See
also Table S1 and Figure S1.at the hematopoietic +23 enhancer element (Nottingham et al.,
2007) (Figures 2A, 2B, and S2A). Although Guenther et al. (2008)
used different specific antibodies than those used in this study,
a direct comparison using our own antibodies in conventional
ChIP experiments suggests that RS4;11 and SEM cells have
similar levels of MLL-N, AF4-C, H3K4Me3, and H3K79Me2
enrichment across RUNX1 (Figure S2A).
Mutations in RUNX1 are commonly associated with AML
but are also found in B-ALL and T-ALL, and are usually inacti-118 Cell Reports 3, 116–127, January 31, 2013 ª2013 The Authorsvating, suggesting that RUNX1 normally
functions as a tumor suppressor (Blyth
et al., 2005; Mangan and Speck, 2011;
Zhang et al., 2012). However, overex-
pression of wild-type RUNX1 can be
oncogenic (Blyth et al., 2005). Thus,
considering the crucial role of RUNX1 inhematopoiesis andmany acute leukemias, we decided to further
explore its potential role in t(4;11) leukemias.
We analyzed the expression of RUNX1 and other target genes
in specific subsets of primary ALL samples, including t(4;11) and
other MLLr samples. Average HOXA9, HOXA10, and CDKN1B
expression is significantly higher in MLLr leukemias than in other
ALL subtypes (Figures 2C–2E and S2B–S2G; Table S2), but
no significant difference in expression levels is seen when com-
paring MLLr and t(4;11) leukemias (in the Eastern Cooperative
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Figure 2. RUNX1 Is a Direct Target of MLL-AF4 and Is Specifically
Upregulated in t(4;11) B-ALLs
(A and B) ChIP-seq data in SEM (A) and in RS4;11 (B) cells across the RUNX1
locus using the antibodies as indicated. Reads were normalized as in Figure 1.
Gray bars highlight the positions of the P1 and P2 promoters as well as the +23
enhancer. Primer sets used for real-time PCR ChIP analysis are shown (red
boxes).
(C–H) The average expression of either HOXA9 (C–E) or RUNX1 (F–H) in three
B-ALL clinical trials separated into different ALL subtypes as indicated.
(C and F) St. Jude ALL patients (Ross et al., 2003). (D and G) COG P9906
clinical trial (Harvey et al., 2010). (E and H) ECOG E2993 clinical trial (Geng
et al., 2012). An asterisk indicates significantly lower average expression for
the leukemia subtype relative to MLLr (C, D, F, and G) or relative to t(4;11)
(E and H). A two-tailed Wilcoxon test was used to calculate p values, and
p values for the different comparisons are in Table S2.
See also Tables S3, S4, and Figure S2.
COncology Group [ECOG] E2993 patient set, the only set where
this MLLr cytogenetic information is available; Figures 2E, S2D,
and S2G; Table S2). Interestingly, similar to what has been
reported previously (Stam et al., 2010; Trentin et al., 2009),
several individual patients display relatively low expression of
both HOXA9 and HOXA10 (Figures 2C–2E and S2B–S2D).
With the exception of E2A-PBX1 leukemias, RUNX1 is signifi-
cantly overexpressed in MLLr leukemias compared to other ALL
subtypes (Figures 2F–2H; Table S2). Importantly, in the ECOG
E2993 patient set, RUNX1 is significantly overexpressed in
t(4;11) samples compared to the other MLLr samples (Figure 2H;
Table S2). Interestingly, the non-t(4;11) MLLr samples in the
ECOG E2993 data set appear to have a lower than average
expression of RUNX1 compared to other leukemia subtypes
(Figure 2H). One possibility is that t(4;11) samples account for
the bulk of the high-expressing RUNX1 samples in the St. Jude
and Children’s Oncology Group (COG) P9906 data sets (Figures
2F and 2G), but unfortunately, because we do not have t(4;11)-
specific data on individual MLLr samples in these data sets,
we cannot test this directly.
These results are also consistent with a recent analysis that
showed RUNX1 is specifically overexpressed in t(4;11) samples
compared to several other childhood ALL samples (Montero-
Ruı´z et al., 2012). It is worth pointing out that the statistically
significant increase in RUNX1 expression in the ECOG E2993
data set only represents a 1.3- to 2.3-fold change in microarray
expression (Tables S3 and S4). However, a small change in
messenger RNA levels for an importantmaster regulatory protein
such as RUNX1 could represent a much bigger effect at the
protein level. Taken as a whole, these results suggest the possi-
bility that RUNX1 could have a unique role in t(4;11)-mediated
leukemogenesis, and we therefore decided to analyze its
possible role on a more detailed molecular level.
MLL-AF4 Directly Regulates RUNX1 and Other Target
Loci by Stabilizing ENL and AF9 Binding
Guenther et al. (2008) previously rejected RUNX1 as a potential
MLL-AF4 target gene because it displayed MLL-N, MLL-C,
AF4-C binding, and H3K4Me3 and H3K79Me2 in both SEM
and the control REH (non-MLLr) cell lines. To determine if
MLL-AF4 is a key regulator of RUNX1 expression, MLL-AF4-
specific siRNA (Thomas et al., 2005) knockdowns were per-
formed in RS4;11 and SEM cell lines. At both the RNA
and protein levels, we saw an MLL-AF4-dependent loss of
RUNX1 expression (Figures 3A–3C). Importantly, we also found
that wild-type MLL had no effect on HOXA9 or RUNX1 regula-
tion (Figure 3B), suggesting that MLL-AF4, but not wild-type
MLL, is key to maintaining the expression of these target
genes.
Because MLL-AF4 is key to maintaining HOXA9 and RUNX1
target gene expression, we wanted to determine if MLL-AF4
was responsible for assembling a specific complex at these
target genes in vivo. The AF4-C portion of MLL-AF4 interacts
directly with wild-type AF9, ENL, and AFF4, and weakly homo-
dimerizes with wild-type AF4, providing an indirect interaction
between MLL-AF4 and the Cyclin T1/CDK9 pTEFb complex
(Benedikt et al., 2011; Biswas et al., 2011; Lin et al., 2010;
Mueller et al., 2007; Yokoyama et al., 2010) (Figure 3D). Inell Reports 3, 116–127, January 31, 2013 ª2013 The Authors 119
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Figure 3. MLL-AF4 Directly Regulates
RUNX1 and Other Target Genes by Stabi-
lizing AF9 and ENL Binding
(A) MLL, MLL-AF4, HOXA9, and RUNX1 real-time
PCR expression in scrambled control siRNA-
treated cells (black bars), MLL-AF4 siRNA-treated
SEM (gray bars), and RS4;11 (white bars) cells.
Data are the mean ± SD (error bars) of three
independent knockdown experiments. In each
individual experiment, control values were set to 1.
(B and C) Western blots as indicated in SEM cells
(B) or RS4;11 cells (C) treated with the siRNAs as
indicated. Proteins were detected using the anti-
bodies indicated except MLL-AF4, which was
detected with an AF4-C antibody.
(D) A summary of AF4 protein interactions.
(E) MLL-N, AF4-C, AFF4, ENL, AF9, and Cyclin T1
ChIP + real-time PCR with scrambled control
versus MLL-AF4 siRNA-treated SEM cells from
(A). Values and error bars represent the mean ± SD
of at least two independent ChIP experiments.
Primer sets are as in Figure 1B, 1C, and 2A.SEM cells, specific siRNA knockdowns of MLL-AF4 reduced
binding of MLL-N, AF4-C, and the MLL-AF4 interacting factors
ENL and AF9 at RUNX1, HOXA9, HOXA10, and CDKN1B
(Figure 3E), but had no effect on the binding of Cyclin T1 and
AFF4. Together, these results indicate that RUNX1, HOXA9,
HOXA10, and CDKN1B are direct targets of MLL-AF4, and
that MLL-AF4 stabilizes the recruitment of AF9 and ENL, but
not Cyclin T1 or AFF4.
t(4;11) Cell Lines Support Higher Levels of RUNX1
Expression Than Other MLL-FP Leukemias
To further analyze the potential importance of RUNX1 in t(4;11)
leukemias, we compared gene expression patterns and complex
assembly at target genes in different MLL-FP cell lines. Typically,
both HOXA9 and HOXA10 are highly expressed in MLL-FP cell
lines and show almost no expression in non-MLL-FP cell lines
(Figure 4A, top and middle). Although RUNX1 gene expression
is complicated by the fact that it appears to be generally higher
in ALLs compared to AMLs, consistent with the primary patient
data in Figure 2H, RUNX1 expression is upregulated in t(4;11)-
containing cells compared to other MLL-FPs (Figure 4A,
bottom). In general, although there are some unique isoforms
specific to different cell types (perhaps reflecting myeloid versus
lymphoid origins), RUNX1 protein levels are higher in t(4;11) cells
than in other MLL-FP cells (Figure 4B).120 Cell Reports 3, 116–127, January 31, 2013 ª2013 The AuthorsInterestingly, although ENL, AF9, and
Cyclin T1 are all expressed in several
cell lines that all express RUNX1 (Fig-
ure 4C), wild-type AF9 and ENL (see Fig-
ure S3) binding is more highly enriched at
RUNX1 and other target genes in t(4;11)
cells than in the other cell lines (Fig-
ure 4D). Although MLL-N ChIP cannot
specifically detect MLL-AF9 or MLL-
ENL (Figure 4D), in combination with the
data in Figure 3, we think the most likelyexplanation for these results is that MLL-AF4 differs from other
MLL-FPs and increases stable AF9 and ENL binding at RUNX1.
RUNX1 Is Required for the Growth of t(4;11) Cells
To determine if RUNX1 expression is important for the leukemic
growth of different MLL-FPs, we used colony-forming assays
coupled with RUNX1 siRNA knockdowns in SEM (t-4;11), MV4-
11 (t-4;11), and THP-1 (MLL-AF9) cells. Cells collected 24 hr after
plating contained50%ofRUNX1mRNAcompared to a nontar-
geting siRNA control (Figure 5A) and resulted in a large reduction
in RUNX1 protein levels (Figure 5B). In SEM and MV4-11 cells,
RUNX1 siRNA treatment inhibited clonogenic ability by 60%
after 14 days, while little effect was observed in THP-1 cells
(Figures 5C and 5D). Similar t(4;11) sensitivity to RUNX1 levels
was observed in cell growth assays comparing SEM cells and
KOPN-8 cells after RUNX1 siRNA treatment (Figures S4A–
S4C). Together, these results suggest that RUNX1 expression
specifically contributes to the growth of t(4;11) cells but not other
common MLL-FPs.
High RUNX1 Expression Correlates with a Poor Clinical
Outcome in ALL
Minimal residual disease (MRD) after treatment is generally
considered to be an indicator of poor prognosis. In the COG
P9906 clinical trial (Harvey et al., 2010), 191 out of 207 ALL
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Figure 4. In t(4;11) Cells, RUNX1 Is Highly
Expressed and Has High Levels of ENL and
AF9 Bound to the Locus
(A) Real-time PCR quantification (see gene
expression analysis in Extended Experimental
Procedures) of HOXA9 (top), HOXA10 (middle),
and RUNX1 (bottom) gene expression in patient
cell lines. The cell lines analyzed are: RS4;11
(t-4;11), SEM (t-4;11), MV4-11 (t-4;11), THP-1
(MLL-AF9), NOMO-1 (MLL-AF9), MONO-MAC1
(MLL-AF9), KOPN-8 (MLL-ENL), ML-2 (MLL-AF6
and an MLL deletion), SHI-1 (MLL-AF6), RCH-ACV
(normal MLL), CCRF-CEM (normal MLL), JURKAT
(normal MLL), and K562 (normal MLL). Error bars
represent the ±SD of two independent experi-
ments. ALL, acute lymphoblastic leukemia; AML,
acute myeloid leukemia; N.D., not detected.
(B) Western blot of RUNX1 in the cell lines as
described in (A) with a short exposure (top panel)
and a long exposure (middle panel).
(C) Western blot of nuclear extracts in the cell
lines indicated and probed with the antibodies as
indicated.
(D)MLL-N, AF4-C, ENL, AF9, and Cyclin T1ChIP in
RS4;11 (dark red bars), SEM (spotted red bars),
MV4-11 (bright red bars), THP-1 (black bars),
KOPN-8 (blue bars), and CCRF-CEM (gray bars)
patient cell lines. The control primer set is from
a random gene-poor region on human chromo-
some 8; otherwise, primer sets are as indicated in
Figures 1B, 1C, and 2A. Error bars represent the
±SD of two independent experiments.
See also Figure S3.patients had MRD data available. As expected, the 67 MRD+
patients had a significantly worse overall survival and relapse-
free survival than the 124 MRD cases (Figures 5E and 5F).
We found that the 124 MRD patients had a significantly lower
average level of RUNX1 expression compared to the 67 MRD+
patients (Figure 5G). Among the 191 patients, 17 harbor MLL-
FPs (MLLr), among which, the 9 patients that were MRD+ at
day 29 had a higher average RUNX1 expression than the 8
patients that did not (Figure 5H). Interestingly, when these
MLLr patients are removed from the data set, the resulting 174Cell Reports 3, 116–127non-MLLr ALL patients showed no signif-
icant correlation betweenRUNX1 expres-
sion and MRD status (Figure 5I). Although
we unfortunately do not have specific
data for t(4;11) leukemias, the correlation
between higher RUNX1 expression levels
and worse clinical outcomes in MLLr
patients suggests thatRUNX1 expression
can directly contribute to leukemogen-
esis in human patients.
RUNX1 Activates Target Genes in
t(4;11) Leukemic Cells
To understand the function of the RUNX1
protein in t(4;11) leukemic cells, we per-
formed RUNX1 ChIP-seq in SEM cellsand identified 11,013 genes directly bound by the RUNX1 protein
(Figures 6A–6D and S5A; Table S5). Interestingly, recent work
has shown that RUNX1 can interact with the wild-type MLL
protein complex (Huang et al., 2011), and we found 3,294 genes
that show a specific overlap between MLL-C/H3K4Me3 binding
and RUNX1 (Figures 6A–6D and S5A; Table S5). RUNX1 also
binds to 617 MLL-AF4 targets (i.e., MLL-N/AF4-C/H3K79Me2
binding sites, Figures 6A and 6C) and 1,664 genes where all
the proteins overlap (Figure 6A; Table S5), including MEF2C
(Figure 6B) and the RUNX1 gene itself (Figure S5A)., January 31, 2013 ª2013 The Authors 121
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Figure 5. High-Level RUNX1 Expression Is Important for t(4;11) Cell
Growth and Correlates with a Poor Clinical Prognosis in MLL-
Rearranged Leukemias
(A) Real-time PCR expression of RUNX1 in THP-1 (MLL-AF9), SEM
(t-4;11), and MV4-11 (t-4;11) cells treated with either a nontargeting
control siRNA or two different RUNX1 siRNAs (#1 and #2). Data for THP-
1#1 and SEM#1 are the mean ± SD of six independent experiments. The
rest of the data are the mean ± SD of three independent experiments.
Samples for gene expression analysis were taken the day of colony assay
plating.
(B) Representative western blots from samples in (A) probed with either
RUNX1 or GAPDH antibodies.
(C) Representative photomicrographs of THP-1 (left column) and SEM (right
column) clonogenic cultures after treatment with either a nontargeting control
(top row) or with RUNX1 siRNA#1 (bottom row).
(D) Colony counts 14 days after plating. Data are the mean ± SD of either six
independent experiments (THP-1#1 and SEM#1) or three independent
experiments (the rest). Three replicates were plated per experiment. Control
samples were set at 100% for each individual experiment.
(E and F) Kaplan-Meier estimates of overall survival (OS) and relapse-free
survival (RFS) based onminimal residual disease (MRD) measured at day 29 of
the end-induction among 191 COG P9906 (Harvey et al., 2010) ALL patients,
log rank test p values.
(G) A total of 67 MRD+ patients had higher average RUNX1 expression levels
than 124 MRD patients (p = 0.00746).
122 Cell Reports 3, 116–127, January 31, 2013 ª2013 The AuthorsMEF2D and JUNBwere both previously identified among a set
of 380 genes tightly regulated by RUNX1 in K562 cells (Penco-
vich et al., 2011), whereas SPI-1 (aka PU.1) is a previously
identified important target gene in RUNX1-mediated leukemo-
genesis (Huang et al., 2008, 2011). MEF2D, JUNB, and SPI-1
are all bound by RUNX1 in SEM cells (Figure 6A, S5A, and
S5B; Table S5). Interestingly, loss of RUNX1 protein levels
appears to have the strongest effect on target genes bound
primarily by RUNX1 and MLL-C (Figures 6E and 6F).
Wild-type MLL knockdowns reduce expression of some MLL-
C/RUNX1-bound gene targets, although not to the same degree
as knockdowns of RUNX1 (Figure 6F). Even though MLL-AF4
does not bind directly to SPI-1 or MEF2D (Figures 6D and
S5A), MLL-AF4-specific knockdowns reduce expression of
both of these target genes, likely due to the reduction of
RUNX1 protein levels (Figure S5C). Importantly, RUNX1 knock-
downs in THP-1 cells did not reduce target gene expression,
and in some cases actually increased expression of RUNX1
target genes (Figure S5D). Taken as a whole, these data suggest
that RUNX1 is functioning as an activator at certain key target
genes in t(4;11) SEM cells, and MLL-C:RUNX1-bound target
genes are particularly sensitive to the loss of RUNX1.
RUNX1 Activates Gene Targets in t(4;11) Cells by
Cooperating with an AF4-MLL Complex
Past work revealed that AF4-MLL is expressed in human
patients (Kowarz et al., 2007) and contributes to t(4;11) leukemo-
genesis (Bursen et al., 2004, 2010). AF4-MLL can alter the epige-
netic profile of target genes by interacting with components of
the SEC and the wild-type MLL-C complex (Benedikt et al.,
2011; Figure 6G), but AF4-MLL does not function primarily
through the activation of canonical MLL-AF4 target genes such
as HOXA9 (Bursen et al., 2010). RUNX1 directly interacts with
the C-terminal SET domain of MLL (Huang et al., 2011), suggest-
ing that RUNX1 could be a component of a wild-typeMLL and an
AF4-MLL:MLL-C complex (Figure 6G, interactions 2 and 3,
respectively).
To determine if RUNX1 exists in a complex with AF4-MLL (see
Figure 6G), we performed immunoprecipitation (IP) experiments
with RS4;11 and SEM nuclear extracts (Figures 6H and 6I). We
found that aRUNX1, aMLL-C, and aAF4-N could coIP a complex
containing RUNX1, MLL-C, wild-type AF4 (black arrowhead),
and a band that corresponds to the cleaved 194 kDa AF4-
MLL protein (white arrowhead; see the legend for Figure S5F
for an explanation of the apparent molecular weights of these
proteins). AF4-N IPs in CCRF-CEM nuclear extracts failed to
detect this 194 KDa AF4-MLL band, and were less enriched for
RUNX1 and the MLL-C complex than comparable IPs in SEM
or RS4;11 cells (Figures S5E and S5F). Together, these results
support the possibility that AF4-MLL exists in a complex with
both MLL-C and RUNX1.(H) Among 17 MLLr patients, 9 patients that were MRD+ had significantly
higher levels of RUNX1 expression than 8 MRD- patients (p = 0.0464, two-
tailed Wilcoxcon test).
(I) Among 174 non-MLLr B-ALL patients, 58 patients who were MRD+ had no
significant increase inRUNX1 expression (p = 0.101, two-tailedWilcoxon test).
See also Figure S4.
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Figure 6. RUNX1 Interacts with the AF4-MLL Complex and Activates Gene Targets
(A) RUNX1 ChIP-seq in SEM cells compared with MLL-C:H3K4Me3 and MLL-N:AF4-C:H3K79Me2 ChIP-seq.
(B–D) Sample ChIP-seq tracks from SEM cells across MEF2C (B), ADAM10 (C), and SPI1/PU.1 (D).
(E) Gene expression analysis by real-time PCR in SEM cells treated with two different RUNX1 siRNAs (gray bars, siRNA#1; white bars, siRNA#2). For each
experiment, the PCR signal was quantified relative to control-treated cells. Results represent the mean ± SD of three independent knockdown experiments.
(F) Western blots as indicated in SEM cells treated with a nontargeting control, RUNX1 siRNA#1, or a wild-type MLL siRNA.
(G) RUNX1 protein complex interactions. RUNX1 can interact with a wild-type AF4 complex (interaction 1), a wild-type MLL complex (interaction 2), and
potentially with an AF4-MLL complex (interaction 3).
(H and I) Immunoprecipitation (IP) experiments using RS4;11 (H) and SEM (I) nuclear extracts. Extracts were IP’d with aIgG (lane 2), aAF4-N (lane 3), aRUNX1
(lane 4) or aMLL-C (lane 5), blotted and probed with the antibodies indicated. Input lanes represent 1% of the amount of extract used for the IPs.
(J) A schematic of theMEF2D, JUNB, JUND, and SPI-1 (aka PU.1) loci showing the approximate location of PCR primer sets (open arrow heads) used for ChIP
analysis. Black box indicates consensus RUNX1 binding motifs in the upstream regulatory region (URE) of SPI-1 (Huang et al., 2008; Huang et al., 2011) and the
first intron of MEF2D (Pencovich et al., 2011). Gray box indicates exon 1 of MEF2D, JUND, JUNB, and SPI-1.
(K–M) ChIP analysis in SEM cells treated with a nontargeting control or RUNX1 siRNA#1 at the targets as indicated using antibodies to AF4-N (K), MLL-C (L), and
RBBP5 (M). Error bars represent the ±SD of three separate PCR reactions.
See also Table S5 and Figure S5.
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Figure 7. MLL-AF4 Activates the RUNX1 Gene and the RUNX1
Protein Interacts with the AF4-MLL Complex and Activates Gene
Targets
(A) RUNX1 can interact with either coactivators or corepressors to cause gene
activation or repression. In t(4;11) cells, RUNX1 can also interact with the AF4-
MLL complex.
(B) In t(4;11) leukemias, MLL-AF4 is expressed from one translocated chro-
mosome, and the MLL-AF4 protein binds to and activates the RUNX1 gene by
stabilizing AF9 and ENL binding. AF4-MLL is expressed from the other
translocated chromosome, and the RUNX1 protein interacts with the AF4-MLL
complex and binds to target genes.RUNX1 siRNA experiments that reduce expression of SPI-1,
MEF2D, JUND, and JUNB (Figure 6F) disrupt binding of
AF4-N, MLL-C, and the MLL-C complex component RBBP5 to
these target genes in vivo (Figures 6J–6M). Further, expression
of MEF2D, JUNB, and SPI-1 is higher in SEM and RS4;11 cells
than in CCRF-CEM cells (Figure S5G), and this correlates with
an increased binding of AF4-N (Figures S5H and S5I). Increased
AF4-N binding is seen even at theMEF2D target gene, which has
approximately equal levels of RUNX1 binding in CCRF-CEM
cells compared to RS4;11 and SEM cells (Figures S5I and
S5J). Unfortunately, AF4-MLL-specific siRNAs failed to reduce
AF4-MLL protein levels (Figures S5K–S5M), and we were not
able to directly test whether AF4-MLL regulates RUNX1 target
genes. However, taken as whole, these data show that RUNX1
activates certain key target genes in t(4;11) pre-B-ALL cells,
and it might accomplish this through recruitment of an
RUNX1:MLL-C:AF4-MLL complex (Figure 7).
DISCUSSION
MLL-FPs are thought to promote leukemogenesis through the
epigenetic activation and maintenance of master regulatory
factors such as HOXA9 and MEIS1, which set up gene expres-
sion networks responsible for constitutive activation of cellular
growth and proliferation pathways. However, in t(4;11) patient
samples, half of the leukemias analyzed do not have elevated
levels of HOXA expression (Stam et al., 2010; Trentin et al.,
2009), and low-level HOXA expression actually correlates with
a worse prognosis (Stam et al., 2010). Furthermore, AF4-MLL
is able to induce leukemias in mice without activating HOXA or
MEIS1 expression (Bursen et al., 2010). Together, these results
suggest that t(4;11) leukemias may activate alternate pathways
that are not dependent on HOXA or MEIS1 expression.
In this analysis, we have identified a 491 target gene set that is
generally highly expressed among MLLr leukemias. RUNX1 is
a unique exception to this in that it is specifically overexpressed
in t(4;11) leukemias (Figure 2H and Montero-Ruı´z et al., 2012).
RUNX1 siRNA knockdowns inhibited clonogenicity of t(4;11)
(SEM and MV4-11) cells but not MLL-AF9 (THP-1) cells, indi-
cating that the oncogenic role for RUNX1 in t(4;11) leukemia
appears to be t(4;11) specific but lineage independent, with
both B-ALL (SEM) and AML (MV4-11) affected.
RUNX1 is known to play critical roles in hematopoiesis
(Mangan and Speck, 2011), and is commonly mutated in
leukemia as a tumor suppressor (Blyth et al., 2005; Mangan
and Speck, 2011; Zhang et al., 2012), including in MLL-ENL
driven leukemias (Nishimoto et al., 2011). However, RUNX1
overexpression in childhood leukemias has been reported
(Mikhail et al., 2002; Niini et al., 2002), whereas oncogenic
function has been identified in other cancers, such as T cell
lymphomas (Blyth et al., 2005).
Recent analyses have suggested that MLL-AF4 promotes
transcription elongation by stabilizing the binding of factors
such as pTEFb, DOT1L, ELL, AFF4, AF9, and ENL at target
genes in vivo (Lin et al., 2010; Yokoyama et al., 2010). AF4-
MLL has been shown to activate gene targets through a similar
ability to promote transcription elongation by interacting with
a pTEFb-containing complex (Benedikt et al., 2011). Here, we124 Cell Reports 3, 116–127, January 31, 2013 ª2013 The Authorsshow that the RUNX1 protein can interact with an AF4-MLL
complex and stabilize its binding to certain gene targets. Thus,
leukemic cells that express AF4-MLL produce an additional
coactivator complex (Benedikt et al., 2011) that may push the
balance toward RUNX1 functioning as a general activator, and
this may have an impact on whether RUNX1 is a tumor sup-
pressor or an oncogene in different cell types (Figure 7A).
Kumar et al. (2011) reported that an AF4-MLL-specific siRNA
had no effect on the growth of the SEM t(4;11) leukemia cell
line. However, as was pointed out in a rebuttal article (Mar-
schalek, 2011), the specific AF4-MLL siRNA used was not likely
to produce a knockdown of the AF4-MLL protein, something we
have now confirmed in our results here (Figures S5K–S5M).
Unfortunately, our own attempt to design an AF4-MLL-specific
siRNA was also unsuccessful (Figures S5K–S5M), likely due to
the stability and low turnover of the AF4-MLL protein (Marscha-
lek, 2011), so the specific role of AF4-MLL remains to be defini-
tively elucidated.
The data we present are consistent with an interplay between
MLL-AF4 and AF4-MLL through the regulation and function of
RUNX1, providing a model of how these oncoproteins could
cooperate on a molecular level (Figure 7B). Such a cooperative
effect between these two fusion proteins could explain why
this particular MLL translocation produces such an aggressive
leukemia with relatively few additional mutations (Bardini et al.,
2011; Bardini et al., 2010).
EXPERIMENTAL PROCEDURES
Chromatin Immunoprecipitation Assays
ChIP (for both real-time PCR and ChIP-seq) experiments were performed as
described in Milne et al. (2009), with several modifications, as outlined in
Extended Experimental Procedures.
ChIP-Seq Analysis
The RS4;11 MLL-N (Akalin et al., 2012) and RS4;11 MLL-N, AF4-C, and
H3K79Me2 (Geng et al., 2012) ChIP-seq data have also been used in separate
studies analyzing DNA hypomethylation at target genes. The SEM MLL-N,
AF4-C, and H3K79Me2 is from Guenther et al. (2008). Regions of overlap for
MLL-N and AF4-C were defined as peaks overlapping in the promoter regions
(± 2 kb to transcriptional start site [TSS]), and for H3K79Me2 as the gene body
regions (2 kb to TSS to +1 kb to transcriptional end SITE [TES]). Further
details of analysis are included in Extended Experimental Procedures.
Patient Data
Gene expressionmicroarray data from three large cohorts of patients with ALL
were analyzed, including the ECOGClinical Trial E2993, (Geng et al., 2012), the
COG Clinical Trial P9906 (Harvey et al., 2010), and the St. Jude Research
Hospital pediatric ALL clinical trial (Ross et al., 2003). Further details are
provided in Extended Experimental Procedures.
Colony Forming Assays
Twenty-four hours after second transfection, cells were plated at a density of 1,
2, or 2.53 105 cells/ml, in triplicate, plated in IMDMMethoCult media (H4100;
STEMCELL Technologies) supplemented with fetal calf serum and cultured for
14 days (37C, 5% CO2) before counting. Colony-forming assays were run in
triplicate with at least three biological repeats.
Western Blotting
A total of 10 mg nuclear extract was loaded per lane on NuPAGE 4%–12%
BisTris gels (Life Technologies) and blotted onto polyvinylidene fluoride
membrane (Immobilon) at 100V for 1 hr using a Tris-glycine blotting buffer.
Blots were probed with the antibodies indicated.
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